secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0001193125-23-257271
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences enters $100M collaboration with Gilead; Gilead gets opt-in rights to pipeline
--------------------------------------------------------------------------------

- Gilead pays $85M upfront cash and $15M equity ($1.16/share, 13.1M shares) for collaboration.
- Gilead licenses its helicase primase inhibitor and NNPI programs to Assembly.
- Gilead has opt-in rights to Assembly programs; exercise fees range from $45M to $125M per program.
- Assembly eligible for up to $330M in milestones per program plus royalties (high single to high teens).
- Gilead has option to purchase additional shares to own up to 29.9% of Assembly under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312523257271/0001193125-23-257271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312523257271/d518980d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-257271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer